Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company's ...

Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time high in the markets. Despite being the f ...

Bristol Myers CEO Christopher Boerner advocates global cost-sharing for drug R&D and criticizes PBMs. Read nore here.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Ozempic and Wegovy would no longer be covered by the state’s health insurance for low-income people under the governor’s ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases. Surging medical costs and regulatory changes hit ...